Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.67 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.63 |
| ▸ | EED | O75530 | 4/20 | 0.57 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.51 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2595218 | 0.93 | EZH2 (0.61) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19620903 | 0.90 | EZH2 (0.69) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19620893 | 0.89 | EZH2 (0.73) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2594806 | 0.88 | EZH2 (0.75) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2592576 | 0.88 | EZH2 (0.66) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19620890 | 0.87 | EZH2 (0.70) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19620822 | 0.86 | EZH2 (0.66) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19620990 | 0.86 | EZH2 (0.68) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL12180088 | 0.86 | EZH2 (0.72) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL17956134 | 0.85 | EZH2 (0.71) | EZH2EZH1EEDSUZ12HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |